Legal & General Group
JSPR icon

Legal & General Group’s Jasper Therapeutics JSPR Stock Holding History

Legal & General Group’s Portfolio JSPR Stock Details JSPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-1,213
Closed -$5.22K – 3476
2025
Q1 		$5.22K Hold
1,213
– – ﹤0.01% 3273
2024
Q4 		$25.9K Hold
1,213
– – ﹤0.01% 2938
2024
Q3 		$22.8K Sell
1,213
-42
-3% -$836 ﹤0.01% 3003
2024
Q2 		$28.5K Buy
+1,255
New +$30.1K ﹤0.01% 2891
2023
Q3 		– Sell
-8,000
Closed -$110K – 3420
2023
Q2 		$110K Buy
+8,000
New +$119K ﹤0.01% 2827

Other funds holding JSPR

SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return
QUSVM
Qiming U.S. Ventures Management Bellevue, Washington $55.6M AUM 98.09% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
IHAM
Integral Health Asset Management New York $2.09B AUM 112.84% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Legal & General Group's JSPR Position: Q2 2025 in Review

Legal & General Group sold out of Jasper Therapeutics (JSPR) in Q2 2025, closing a stake of 1,213 shares — an estimated $5.22K sold.

Legal & General Group first reported a position in JSPR in Q2 2023 and held it in 5 quarters. The position peaked at $110K in Q2 2023. 65 funds tracked by Wall St. Rank hold JSPR as of Q2 2025.

  • Legal & General Group reported no remaining Jasper Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Legal & General Group sold 1,213 Jasper Therapeutics shares in Q2 2025, an estimated $5.22K.
  • Legal & General Group first reported a position in Jasper Therapeutics in Q2 2023 and held it in 5 quarters.
  • Legal & General Group's Jasper Therapeutics position peaked at $110K in Q2 2023.
  • 65 funds tracked by Wall St. Rank held Jasper Therapeutics as of Q2 2025.

Based on Legal & General Group's 13F filing for Q2 2025, filed 12 Aug 2025.